IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v8y2024i6d10.1007_s41669-024-00512-8.html
   My bibliography  Save this article

Economic Impact of Bladder Cancer in the USA

Author

Listed:
  • Otavio Clark

    (Oracle®)

  • Tulio Sarmento

    (Oracle®)

  • Anthony Eccleston

    (Pfizer Inc)

  • Julia Brinkmann

    (Pfizer Inc)

  • Renato Picoli

    (Oracle®)

  • Vamsi Daliparthi

    (Oracle®)

  • Jorine Voss

    (Oracle®)

  • Sanjana Chandrasekar

    (Pfizer Inc)

  • Allison Thompson

    (Pfizer Inc)

  • Jane Chang

    (Pfizer Inc)

Abstract

Introduction Incidence and mortality for bladder cancer has changed very little over the past 20 years. Approximately 40% of patients with high-risk nonmuscle invasive bladder cancer eventually recur/progress. It is important to understand the economic impact of disease recurrence/progression in bladder cancer. Our aim was to estimate and understand the direct costs associated with the treatment of bladder cancer from the payer’s perspective in the USA, in the year of 2021, including costs for both newly diagnosed bladder cancer (stages 0a–IV) and recurrent patients. Methods An economic model was constructed to calculate the number of patients receiving each treatment modality at every stage of disease and their respective costs. Epidemiological data were based on the CancerMPact Patient Metrics (PM) database and treatment modality data retrieved from CMP Treatment Architecture (TA), 2021 version. Resource utilization and costs were obtained from medical literature and public data sources. Only direct costs were considered. Results There were an estimated 83,532 newly diagnosed patients with bladder cancer of all stages in 2021 with a projected total cost of treatment of ~$2.6 billion. Average cost per newly diagnosed patient varied from $19,521 (stage 0a) to $169,533 (metastatic disease). Cost profile differed substantially among the stages of disease. For the 75,760 patients that were expected to have a recurrence in 2021, an additional cost of ~$3.9 billion was estimated at an average cost per patient of $52,179. The expected total cost to treat newly diagnosed and newly recurrent patients is reported in this model, with the total cost in 2021 estimated to exceed $6.5 billion. Conclusions Treatment and resource costs increase for bladder cancer as the disease recurs/progresses. More effective treatments that can delay recurrence/progression may reduce the economic burden associated with bladder cancer.

Suggested Citation

  • Otavio Clark & Tulio Sarmento & Anthony Eccleston & Julia Brinkmann & Renato Picoli & Vamsi Daliparthi & Jorine Voss & Sanjana Chandrasekar & Allison Thompson & Jane Chang, 2024. "Economic Impact of Bladder Cancer in the USA," PharmacoEconomics - Open, Springer, vol. 8(6), pages 837-845, November.
  • Handle: RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00512-8
    DOI: 10.1007/s41669-024-00512-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-024-00512-8
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-024-00512-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00512-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.